Leadership Team
BioAge Labs, a clinical-stage biopharmaceutical company, boasts a diverse and experienced leadership team driving its mission to develop therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Key members include:
CEO and Co-Founder
- Kristen Fortney, PhD: Serving as CEO, President, and Treasurer since April 2015. Her annual compensation is approximately $1.38 million, with a 3.38% direct ownership of company shares.
Co-Founder
- Eric Morgen: Leads human cohort partnerships and computational efforts for drug target discovery. His background spans artificial intelligence, medicine, and computational biology.
Chief Medical Officer & Executive VP of Research
- Paul Rubin: Heads clinical development of BioAge's aging-targeted therapies. He brings extensive experience from pharmaceutical and biotech industries.
Chief Financial Officer
- Dov Goldstein: Brings over 20 years of strategic financial and operational experience in healthcare, having held leadership roles at various biotech companies.
Other Key Positions
- Chief Business Officer & Therapeutic Area Head of Brain Aging
- Senior Vice President of Regulatory Affairs
- Senior Vice President of Translational Aging Biology
- Chief Strategy Officer
Board of Directors
- Jean-Pierre Garnier, PhD: Recently appointed Chair, former CEO of GlaxoSmithKline
- James Healy, MD, PhD: Former Chair, continuing board member and managing partner of Sofinnova Investments The leadership team combines seasoned executives and visionary co-founders, each contributing significant expertise to advance BioAge Labs' innovative approach to treating age-related diseases.
Core Technology
BioAge Labs leverages a data-driven approach to understand and target the biology of human aging, focusing on cardiometabolic and age-related diseases. Their core technology encompasses several key components:
Data Collection and Analysis
BioAge Labs utilizes extensive longitudinal human longevity data, primarily from blood samples, including:
- Proteomics: Analyzing 5,000 proteins
- Metabolomics: Examining several thousand metabolites
- Gene expression: Analyzing tens of thousands of gene expressions using RNA-Seq
AI and Machine Learning
Advanced AI and ML algorithms are employed to analyze the vast dataset, identifying key molecular factors that change with age and predict future health outcomes. This approach distinguishes between healthy and unhealthy aging profiles.
Longitudinal Omics and Functional Assessments
The platform integrates longitudinal omics data with serial functional assessments, modeling aging-related physical, cognitive, and functional decline. This method captures healthspan trajectories starting from healthy individuals.
Discovery and Development
BioAge's platform identifies translational drug targets by analyzing the complex interplay of biological pathways related to metabolic aging. An unbiased approach is used to identify targets, which are then validated through an in-house translational aging core in naturally aged mice.
Collaboration and Integration
The company collaborates with industry leaders like Novartis, combining their human longevity datasets with external expertise to discover and validate new therapeutic drug targets.
Bespoke Data Science Ecosystem
BioAge has developed a custom data science ecosystem utilizing AI and ML to generate insights from human aging cohorts, crucial for identifying and validating potential therapeutic targets. By integrating these elements, BioAge Labs aims to develop therapies targeting fundamental biological pathways of human aging, with the goal of improving health outcomes and increasing healthspan.
Industry Peers
BioAge Labs operates within the biotechnology industry, focusing on aging and age-related metabolic diseases. Key industry peers and competitors include:
UNITY Biotechnology
A significant competitor developing therapeutics targeting diseases of aging, listed on NASDAQ under the ticker symbol UBX.
FibroGen
Known for developing innovative therapeutics in areas such as anemia and fibrosis, aligning with BioAge Labs' focus on metabolic and aging-related diseases.
Amgen
A major biotechnology company with a robust pipeline of therapeutics targeting metabolic diseases, including obesity and related conditions.
Novo Nordisk
A prominent player in the biotechnology sector, with a strong focus on diabetes and obesity treatments, presenting significant competition in the metabolic diseases space.
Regeneron Pharmaceuticals
Known for its innovative approach to drug development, particularly in metabolic disorders, posing a challenge to BioAge Labs with cutting-edge technologies and therapies.
Vertex Pharmaceuticals
While primarily focused on rare diseases and genetic disorders, Vertex presents competition in the broader biotech space due to innovative approaches and significant resources.
Other Competitors
Additional companies in the broader biotechnology and healthcare space that may overlap with BioAge Labs' research areas include:
- DiaCarta
- Mission Bio
- Quadrants Scientific These competitors highlight the dynamic and competitive nature of the aging and metabolic diseases biotechnology sector, driving innovation and advancements in therapeutic development.